Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVOLIN N vs NOVOLIN 70/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
Treatment of diabetes mellitus (type 1 and type 2) to improve glycemic control
Diabetes mellitus requiring insulin therapy for glycemic control
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours.
Metabolized by insulin-degrading enzyme (IDE) primarily in the liver and kidneys.
No specific dose adjustment required for renal impairment; monitor glucose closely.
GFR >60 m L/min: No adjustment. GFR 30-60 m L/min: Monitor glucose, may need dose reduction due to prolonged insulin action. GFR <30 m L/min: Reduce dose by 25-50% and monitor closely.
Never share a NOVOLIN N Flex Pen, Pen Fill cartridge, or vial between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Insulin is not teratogenic. Poor glycemic control increases risks of congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia (third trimester).
Insulin does not cross the placenta in significant amounts. No known teratogenic risk. Poor glycemic control increases risk of congenital anomalies, macrosomia, and neonatal hypoglycemia.
NOVOLIN N (NPH insulin) is an intermediate-acting insulin with onset of action in 2-4 hours, peak at 4-12 hours, and duration up to 18-24 hours. It should be resuspended by rolling the vial or pen gently at least 10 times until a uniform milky white suspension appears before each use. Administer subcutaneously, typically before breakfast and/or before dinner. Because of its peak activity, patients are at higher risk for hypoglycemia during the late morning (if AM dose) or during the night (if PM dose). Adjust doses based on blood glucose trends, especially fasting and pre-meal values. Be aware that NPH insulin has a variable absorption profile; consider switching to insulin analogs if hypoglycemia or glycemic variability is problematic. Do not use in insulin pumps or intravenous administration.
NOVOLIN 70/30 is a biphasic insulin containing 70% NPH (intermediate-acting) and 30% regular (short-acting) insulin. It should be administered subcutaneously 30 minutes before meals to align peak insulin action with postprandial glucose rise. Due to its fixed ratio, it is less flexible than basal-bolus regimens and may not be optimal for patients with variable meal schedules or erratic glucose patterns. Avoid use in insulin pumps. Shake or roll vial/pen gently to resuspend before each use.
No interactions on record
No interactions on record
Common clinical questions about NOVOLIN N vs NOVOLIN 70/30, answered by our medical review team.
NOVOLIN N is a Insulin that works by Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.. NOVOLIN 70/30 is a Insulin that works by Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVOLIN N and NOVOLIN 70/30 depend on the specific clinical indication. These are both Insulin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVOLIN N is: Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.. The standard adult dose of NOVOLIN 70/30 is: Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVOLIN N and NOVOLIN 70/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVOLIN N is classified as Category C. Insulin is not teratogenic. Poor glycemic control increases risks of congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia (third trimester).. NOVOLIN 70/30 is classified as Category C. Insulin does not cross the placenta in significant amounts. No known teratogenic risk. Poor glycemic control increases risk of congenital anomalies, macrosomia, and neonatal hypogl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily metabolized by insulin-degrading enzyme (IDE) in the liver, kidneys, and peripheral tissues.
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible.
~55% bound to albumin and beta-globulins.
<5% bound to serum proteins (primarily albumin).
0.1-0.2 L/kg, approximating extracellular fluid volume, indicating limited extravascular distribution.
Approximately 0.3-0.6 L/kg; reflects distribution into extracellular fluid and tissues.
Subcutaneous: 55-80% due to enzymatic degradation at injection site. Intravenous: 100%.
Subcutaneous: 100% (complete absorption).
No specific dose adjustment required for hepatic impairment; monitor glucose closely.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% due to impaired gluconeogenesis. Child-Pugh Class C: Avoid use or reduce dose significantly (e.g., by 50-75%) with close monitoring.
Individualized based on blood glucose goals. Typical starting dose: 0.25-0.5 units/kg/day subcutaneously in 2 divided doses.
Children: 0.5-1 unit/kg/day subcutaneously, typically administered as 2-3 injections before meals; individualize based on age and blood glucose. For adolescents: similar to adult dosing.
Start with lower doses (e.g., 0.25-0.5 units/kg/day) and titrate slowly to avoid hypoglycemia; monitor renal function.
Start with lower doses (e.g., 0.2-0.3 unit/kg/day) due to increased risk of hypoglycemia; titrate slowly; monitor renal function and cognitive status.
Changes in insulin strength, manufacturer, type, or method of administration should be done under close medical supervision to prevent hypoglycemia or hyperglycemia.
No specific food interactions expected with NPH insulin. However, patients should maintain consistent carbohydrate intake timing and amount relative to insulin dose to prevent hypoglycemia or hyperglycemia. Alcohol consumption may increase the risk of hypoglycemia, especially if consumed on an empty stomach or with exercise. Grapefruit is not known to interact with insulin.
Meal timing and composition significantly affect glycemic response. Administer insulin 30 minutes before a meal that contains carbohydrates to avoid postprandial hyperglycemia or hypoglycemia. Rapid absorption of simple sugars may require dose adjustments. Alcohol can increase hypoglycemic risk; limit intake and do not drink on an empty stomach. No specific food-drug interactions known.
Insulin is endogenous protein; negligible amounts in breast milk. M/P ratio not applicable. Safe during breastfeeding.
Insulin is excreted in breast milk in negligible amounts. No adverse effects reported. M/P ratio not applicable due to endogenous peptide.
Increased insulin resistance in second and third trimesters typically requires dose increases (often 50-100% above pre-pregnancy doses). Frequent adjustments needed.
Increased insulin requirements, especially in second and third trimesters due to insulin resistance. Dose adjustments frequently required. Monitor and titrate individually.
Roll the vial or pen gently between your palms at least 10 times before each use to resuspend the insulin; do not shake vigorously.,Inject the insulin subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites to prevent lipodystrophy.,Monitor your blood glucose regularly, especially before meals and at bedtime, and be aware that NPH insulin peaks 4-12 hours after injection, which increases hypoglycemia risk.,Recognize symptoms of hypoglycemia (e.g., sweating, tremor, confusion) and treat immediately with fast-acting sugar like juice or glucose tablets.,Store unopened vials/pens in the refrigerator; once opened, keep at room temperature and discard after 28 days.,Do not skip meals and maintain consistent carbohydrate intake to avoid blood glucose swings.,Carry a source of sugar and medical identification indicating diabetes and insulin use.
Shake or roll the vial or pen gently until it looks uniformly cloudy before each injection.,Inject your dose subcutaneously into abdomen, thigh, or upper arm, rotating sites within the same region.,Take your insulin 30 minutes before a meal; it has both peak and long-acting components.,Do not skip meals after injection to prevent hypoglycemia.,Always keep a fast-acting glucose source (e.g., glucose tablets, juice) available for low blood sugar.,Do not share insulin pens or needles with others.,Store unused insulin in the refrigerator; keep the one in use at room temperature for up to 28 days.,Monitor your blood glucose regularly and report any unusual patterns or severe hypo/hyperglycemia to your provider.